Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

被引：0
|
作者：
G E Konecny
R Glas
J Dering
K Manivong
J Qi
R S Finn
G R Yang
K-L Hong
C Ginther
B Winterhoff
G Gao
J Brugge
D J Slamon
机构：
[1] David Geffen School of Medicine,Division of Hematology
[2] University of California Los Angeles,Oncology, Department of Medicine
[3] Mayo Clinic,Division of Gynecologic Surgery, Department of Obstetrics and Gynecology
[4] Harvard Medical School,Department of Cell Biology
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
Src; Eph2A; FAK; uPA; dasatinib; ovarian cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1699 / 1708
页数：9
相关论文
共 50 条
  • [1] Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
    Konecny, G. E.
    Glas, R.
    Dering, J.
    Manivong, K.
    Qi, J.
    Finn, R. S.
    Yang, G. R.
    Hong, K-L
    Ginther, C.
    Winterhoff, B.
    Gao, G.
    Brugge, J.
    Slamon, D. J.
    BRITISH JOURNAL OF CANCER, 2009, 101 (10) : 1699 - 1708
  • [2] E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
    Bougen-Zhukov, Nicola
    Decourtye-Espiard, Lyvianne
    Mitchell, Wilson
    Redpath, Kieran
    Perkinson, Jacqui
    Godwin, Tanis
    Black, Michael A.
    Guilford, Parry
    CANCERS, 2022, 14 (07)
  • [3] Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
    Xiao, Juan
    Xu, Manman
    Hou, Teng
    Huang, Yongwen
    Yang, Chenlu
    Li, Jundong
    MOLECULAR MEDICINE REPORTS, 2015, 12 (03) : 3249 - 3256
  • [4] Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells
    Teoh, Deanna
    Ayeni, Tina A.
    Rubatt, Jennifer M.
    Adams, David J.
    Grace, Lisa
    Starr, Mark D.
    Barry, William T.
    Berchuck, Andrew
    Murphy, Susan K.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : 187 - 192
  • [5] Dasatinib, a Multikinase Inhibitor: Therapy, Safety, and Appropriate Management of Adverse Events
    Shayani, Sepideh
    THERAPEUTIC DRUG MONITORING, 2010, 32 (06) : 680 - 687
  • [6] Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies
    Fauziya
    Gupta, Akash
    Nadaf, Arif
    Ahmad, Shadaan
    Hasan, Nazeer
    Imran, Mohammad
    Sahebkar, Amirhossein
    Jain, Gaurav Kumar
    Kesharwani, Prashant J.
    Ahmad, Farhan
    MEDICAL ONCOLOGY, 2023, 40 (06)
  • [7] Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells
    Rice, Lori
    Lepler, Sharon
    Pampo, Christina
    Siemann, Dietmar W.
    CLINICAL & EXPERIMENTAL METASTASIS, 2012, 29 (02) : 133 - 142
  • [8] Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells
    Lori Rice
    Sharon Lepler
    Christina Pampo
    Dietmar W. Siemann
    Clinical & Experimental Metastasis, 2012, 29 : 133 - 142
  • [9] Src inhibitor dasatinib sensitized gastric cancer cells to cisplatin
    Huizhen Wang
    Yida Lu
    Mingliang Wang
    Aolin Shen
    Youliang Wu
    Xin Xu
    Yongxiang Li
    Medical Oncology, 40
  • [10] Src inhibitor dasatinib sensitized gastric cancer cells to cisplatin
    Wang, Huizhen
    Lu, Yida
    Wang, Mingliang
    Shen, Aolin
    Wu, Youliang
    Xu, Xin
    Li, Yongxiang
    MEDICAL ONCOLOGY, 2022, 40 (01)
12345